Zhengye Biotechnology Holding (ZYBT) Receivables - Other (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Receivables - Other for 3 consecutive years, with $104052.5 the latest figure, recorded in Q4 2025.

• Quarterly Receivables - Other rose 1.28% year-over-year to $104052.5 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $104052.5 (up 1.28% YoY) and the FY2025 annual result came in at $3.3 million, up 829.17% from the prior year.
• Receivables - Other improved to $104052.5 in Q4 2025 per ZYBT's latest filing, from -$977000.0 in the prior quarter.
• Over the last five years, Receivables - Other for ZYBT reached as high as $180831.4 in Q4 2023 and fell as low as -$977000.0 in Q2 2025.
• A 3-year average of -$147343.7 and a median of $103396.9 in 2024 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2024 — Receivables - Other sank 43.18% — and 2025, when it grew 1.28%.
• Year by year, Receivables - Other stood at $180831.4 in 2023, then plunged by 43.18% to $102741.2 in 2024, then grew by 1.28% to $104052.5 in 2025.
• According to Business Quant data, Receivables - Other over the past three periods registered $104052.5, -$977000.0, and $102741.2 for Q4 2025, Q2 2025, and Q4 2024 respectively.